[go: up one dir, main page]

WO2004069204A3 - Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins - Google Patents

Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins Download PDF

Info

Publication number
WO2004069204A3
WO2004069204A3 PCT/US2004/003861 US2004003861W WO2004069204A3 WO 2004069204 A3 WO2004069204 A3 WO 2004069204A3 US 2004003861 W US2004003861 W US 2004003861W WO 2004069204 A3 WO2004069204 A3 WO 2004069204A3
Authority
WO
WIPO (PCT)
Prior art keywords
acute phase
antigenic molecule
phase protein
fusion proteins
molecule complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/003861
Other languages
French (fr)
Other versions
WO2004069204A2 (en
Inventor
Pramod K Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut Health Center
Original Assignee
University of Connecticut Health Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut Health Center filed Critical University of Connecticut Health Center
Priority to AU2004208848A priority Critical patent/AU2004208848A1/en
Priority to EP04708276A priority patent/EP1594535A4/en
Priority to CA002515107A priority patent/CA2515107A1/en
Publication of WO2004069204A2 publication Critical patent/WO2004069204A2/en
Publication of WO2004069204A3 publication Critical patent/WO2004069204A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to complexes and fusion proteins comprising an acute phase protein and an antigenic molecule, for use in the treatment or prevention of a disease. The invention specifically provides for complexes comprising an acute phase protein noncovalently bound to, or alternatively crosslinked to, an antigenic molecule. The invention also specifically provides fusion proteins comprising an acute phase protein fused via a peptide bond to an antigenic molecule.
PCT/US2004/003861 2003-02-04 2004-02-04 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins Ceased WO2004069204A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2004208848A AU2004208848A1 (en) 2003-02-04 2004-02-04 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
EP04708276A EP1594535A4 (en) 2003-02-04 2004-02-04 ACUTE PHASE ANTIGEN-PROTEIN MOLECULE COMPLEXES AND FUSION PROTEINS
CA002515107A CA2515107A1 (en) 2003-02-04 2004-02-04 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44476803P 2003-02-04 2003-02-04
US60/444,768 2003-02-04

Publications (2)

Publication Number Publication Date
WO2004069204A2 WO2004069204A2 (en) 2004-08-19
WO2004069204A3 true WO2004069204A3 (en) 2004-11-25

Family

ID=32850927

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/003861 Ceased WO2004069204A2 (en) 2003-02-04 2004-02-04 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins

Country Status (4)

Country Link
EP (1) EP1594535A4 (en)
AU (1) AU2004208848A1 (en)
CA (1) CA2515107A1 (en)
WO (1) WO2004069204A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008515389A (en) * 2004-08-20 2008-05-15 ノボ ノルディスク アクティーゼルスカブ Hemopexin fusion protein
WO2011029980A1 (en) * 2009-09-11 2011-03-17 Proyecto De Biomedicina Cima, S.L. Therapeutic compositions for the treatment of hpv-induced diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091787A1 (en) * 2000-06-02 2001-12-06 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EPSTEIN H.F.: "Acute-phase proteins and other systemic responses to inflammation", NEJM, vol. 340, no. 6, February 1999 (1999-02-01), pages 448 - 454, XP008003139 *
ROVERE ET AL.: "The long pentraxin PTX3 binds to apoptopic cell and regulates their clearance by antigen-presenting dendritic cells", BLOOD, vol. 96, no. 13, December 2000 (2000-12-01), pages 4300 - 4306, XP002230331 *
See also references of EP1594535A4 *

Also Published As

Publication number Publication date
EP1594535A2 (en) 2005-11-16
EP1594535A4 (en) 2006-07-12
WO2004069204A2 (en) 2004-08-19
AU2004208848A1 (en) 2004-08-19
CA2515107A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
WO2000078344A8 (en) Prion protein peptides and uses thereof
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
WO2002079232A3 (en) Reducing the immunogenicity of fusion proteins
WO2004069206A3 (en) Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
WO2004110472A3 (en) Fusion proteins
WO2002062377A3 (en) Combined use of factor vii polypeptides and factor viii polypeptides
WO2003090686A3 (en) Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2004010957A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2005049073A3 (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
EP2360259A3 (en) Promyostatin peptides and methods of using same
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2002081505A3 (en) Peptide for the diagnosis and therapy of alzheimer's disease
AU2002354806A1 (en) Parathyroid hormone antibodies and related methods
WO2002098456A3 (en) Antigens and vectors for vaccination
WO2005051902A3 (en) Modified mscl protein channel
WO2006060021A3 (en) Bifunctional fusion proteins containing the flt3 ligand
AU2003203002A1 (en) Polymeric conjugates for delivery of mhc-recognized epitopes via peptide vaccines
EE04855B1 (en) Anticoagulant compound, process for its preparation, pharmaceutical preparation containing it and therapeutic use thereof
WO2005001048A3 (en) Preparation and application of anti-tumor bifunctional fusion proteins
AUPQ712000A0 (en) Antigenic peptide fragments of VapA protein, and uses thereof
WO2004069204A3 (en) Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
WO2004069208A3 (en) Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
WO2004069205A3 (en) Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2515107

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004208848

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004208848

Country of ref document: AU

Date of ref document: 20040204

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2004708276

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004208848

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004708276

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004708276

Country of ref document: EP